Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Last 14 days
An Open-Label, Single-Arm, Multiple-Dose, Phase 3 Safety and Efficacy Study of Cebranopadol in Participants With Moderate to Severe Acute Pain With Surgical or Non-Surgical Origin
A Randomized, Double-Blind, Multiple-Dose Study to Assess the Ability of Cebranopadol to Suppress Withdrawal Signs and Symptoms in Adults With Chronic Pain Who Are Physically Dependent on Opioids
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)